Enhancement of DNA vaccine-induced immune responses by a 72-bp element from SV40 enhancer

Chinese Medical Journal

Volumn 120, Issue 6, 2007, Pages 496-502

  Li, Hai Shan ^a   Liu, Yong ^a   Li, Ding Feng ^a   Zhang, Ran Ran ^a   Tang, Hai Li ^a   Zhang, Yu Wei ^a   Huang, Wei ^a   Liu, Ying ^a   Peng, Hong ^a   Xu, Jian Qing ^a   Hong, Kun Xue ^a   Shao, Yi Ming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

DNA vaccines; Prime boost; SV40 enhancer; Tiantan strain; Vaccinia

Indexed keywords

DNA VACCINE; GAG PROTEIN; PLASMID DNA; PLASMID VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA IMMUNIZATION; ENHANCER REGION; GENE EXPRESSION; GENE INSERTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PROMOTER REGION; SIMIAN VIRUS 40; TH1 CELL; TH2 CELL; VACCINIA VIRUS; VIRUS REPLICATION; VIRUS STRAIN;

EID: 34047133231     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200703020-00012     Document Type: Article

References (20)

1. Robinson HL, Torres CA. DNA vaccines. Semin Immnunol 1997; 9: 271-283.
2. Donnelly JJ, Wahren B, Liu MA. DNA vaccine: progress and challenges. J Immunol 2005; 175: 633-639.
3. Bremner KH, Seymour LW, Pouton C. W. Harnessing nuclear localization pathways for transgene delivery. Curr Opin Mol Ther 2001; 3: 170-177.
4. James MB, Giorgio TD. Nuclear-associated plasmid, but not cell-associated plasmid, is correlated with transgene expression in cultured mammalian cells. Mol Ther 2000; 1: 339-346.
5. Johnson-Saliba M, Jans DA. Gene therapy: optimising DNA delivery to the nucleus. Curr Drug Targets 2001; 2: 371-399.
6. Kamiya H, Tsuchiya H, Yamazaki J, Harashima H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors. Adv Drug Deliv Rev 2001; 52: 153-164.
7. Tachibana R, Harashima H, Shinohara Y, Kiwada H. Quantitative studies on the nuclear transport of plasmid DNA and gene expression employing nonviral vectors. Adv Drug Delivery Rev 2001; 52: 219-226.
8. Dean DA, Dean BS, Muller S, Smith LC. Sequence requirements for plasmid nuclear import. Exp Cell Res 1999; 253: 713-722.
9. Li S, MacLaughlin FC, Fewell JG, Gondo M, Wang J, Nicol F, et al. Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid. Gene Ther 2001; 8: 494-497.
10. Su L, Graf M, Zhang Y, von Briesen H, Xing H, Kostler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. J Virol 2000; 74: 11367-11376.
11. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997; 23: 1094-1097.
12. Earl PL, Cooper N, Moss B. Preparation of cell cultures and vaccinia virus stocks. In: Brent R, Ausubel FM, Kingston RE, Moore DD, Seidman JG, Smith JA, et al, eds. Current protocols in molecular biology. North Carolina: ULR; 1991: 1-117.
13. Brunner S, Sauer T, Carotta S, Cotten M, Saltik M, Wagner E. Cell cycle dependence of gene transfer by lipoplex polyplex and recombinant adenovirus. Gene Ther 2000; 7: 401-407.
14. Dean DA. Peptide nucleic acids: versatile tools for gene therapy strategies. Adv Drug Delivery Rev 2000; 44: 81-95.
15. Wilson GL, Dean BS, Wang Q and Dean DA. Nuclear import of plasmid DNA in digitonin-permeabilized cells requires both cytoplasmic factors and specific DNA sequences. J Biol Chem 1999; 274: 22025-22032.
16. Schirmbeck R, Konig-Merediz SA, Riedl P, Kwissa M, Sack F, Schroff M, et al. Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. J Mol Med 2001; 79: 343-350.
17. Mesika A, Kiss V, Brumfeld V, Ghosh G, Reich Z. Enhanced intracellular mobility and nuclear accumulation of DNA plasmids associated with a karyophilic protein. Hum Gene Ther 2005; 16: 200-208.
18. Talsma SS, Babensee JE, Murthy N, Williams IR. Development and in vitro validation of a targeted delivery vehicle for DNA vaccines. J Control Release 2006; 112:271-279.
19. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21: 163-165.
20. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003; 77: 799-803.